Goldman Sachs analysts removed AstraZeneca (AZN) from the firm’s European Conviction List as part of its monthly update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Mereo Biopharma Stock (MREO) Collapses over 90% after Failed Trials
- MSFT, CRM, ORCL: Why Evercore Names These 3 Software Stocks as ‘Top Picks for 2026’
- AstraZeneca Targets Chemo-Ineligible Lung Cancer Patients With New Osimertinib Trial
- AstraZeneca Moves CAR-T Into Autoimmune Diseases, Adding Long-Term Upside to AZN’s Pipeline
- AstraZeneca says to end U.S. commercial sales of Andexxa